The efficacy of SACLAC as a potent AC inhibitor has been presented [5,31,32], and a large literature exists on the GCS inhibitors such as D-threo-PDMP, D-threo-PPMP, eliglustat, and the like, for treatment of lipid storage diseases as well as cancer [33]. This evidence concerns the gene ASAH1 and Lipid storage disease.